Compare HII & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HII | INCY |
|---|---|---|
| Founded | 1886 | 1991 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Marine Transportation | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 17.0B |
| IPO Year | 2010 | 1994 |
| Metric | HII | INCY |
|---|---|---|
| Price | $406.39 | $90.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 22 |
| Target Price | ★ $397.83 | $100.76 |
| AVG Volume (30 Days) | 414.1K | ★ 1.4M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | 10.24 | ★ 4173.33 |
| EPS | ★ 15.39 | 6.41 |
| Revenue | ★ $12,484,000,000.00 | $3,394,635,000.00 |
| Revenue This Year | $4.58 | $10.97 |
| Revenue Next Year | $6.30 | $10.24 |
| P/E Ratio | $27.24 | ★ $14.50 |
| Revenue Growth | 8.23 | ★ 13.67 |
| 52 Week Low | $177.42 | $53.56 |
| 52 Week High | $460.00 | $112.29 |
| Indicator | HII | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 33.51 |
| Support Level | $404.32 | $82.66 |
| Resistance Level | $434.07 | $92.86 |
| Average True Range (ATR) | 12.75 | 2.32 |
| MACD | -2.91 | -0.40 |
| Stochastic Oscillator | 10.47 | 6.06 |
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.